BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, Hashim A, Kamal E, Mehrez M, Attia D. The NAFLD-MAFLD debate: Eminence vs evidence. Liver Int 2021;41:255-60. [PMID: 33220154 DOI: 10.1111/liv.14739] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
2 Alharthi J, Eslam M. Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr 2021;10:696-8. [PMID: 34760977 DOI: 10.21037/hbsn-21-269] [Reference Citation Analysis]
3 Mantovani A. MAFLD vs NAFLD: Where are we? Dig Liver Dis 2021;53:1368-72. [PMID: 34108096 DOI: 10.1016/j.dld.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
5 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
7 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Alem SA, Gaber Y, Abdalla M, Said E, Fouad Y. Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. Journal of Hepatology 2021;74:1261-2. [DOI: 10.1016/j.jhep.2021.01.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Eslam M, George J. MAFLD: Now is the time to capitalize on the momentum. J Hepatol 2021;74:1262-3. [PMID: 33587953 DOI: 10.1016/j.jhep.2021.02.002] [Reference Citation Analysis]
10 Fouad Y, Gomaa A, Attia D. The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt. Ther Adv Endocrinol Metab 2021;12:20420188211054678. [PMID: 34733466 DOI: 10.1177/20420188211054678] [Reference Citation Analysis]
11 Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. Journal of Hepatology 2021;74:1254-6. [DOI: 10.1016/j.jhep.2020.12.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
12 Ghaffari R, Yang DS, Kim J, Mansour A, Wright JA Jr, Model JB, Wright DE, Rogers JA, Ray TR. State of Sweat: Emerging Wearable Systems for Real-Time, Noninvasive Sweat Sensing and Analytics. ACS Sens 2021;6:2787-801. [PMID: 34351759 DOI: 10.1021/acssensors.1c01133] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
13 Yang RX, Zou ZS, Zhong BH, Deng H, He FP, Shi JP, Zhao CY, Mi YQ, Zhou YJ, Di FS, Zheng RD, Du Q, Shang J, Popovic B, Chen J, Fan JG. The pathologic relevance of metabolic criteria in patients with biopsy-proven non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00112-0. [PMID: 34246549 DOI: 10.1016/j.hbpd.2021.06.002] [Reference Citation Analysis]
14 Policarpo S, Carvalhana S, Craciun A, Crespo RR, Cortez-Pinto H. Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake? Nutrients 2022;14:1335. [PMID: 35405948 DOI: 10.3390/nu14071335] [Reference Citation Analysis]
15 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
16 Chen X, Chen S, Pang J, Tang Y, Ling W. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol 2021:S0168-8278(21)00421-9. [PMID: 34153396 DOI: 10.1016/j.jhep.2021.06.013] [Reference Citation Analysis]
17 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 30.0] [Reference Citation Analysis]
18 Fouad Y, Méndez-Sánchez N, Zheng MH. One Not Like the Other: The weakness of the blood sugar-MAFLD analogy. J Hepatol 2021:S0168-8278(21)02117-6. [PMID: 34678406 DOI: 10.1016/j.jhep.2021.10.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Han AL. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. Diabetol Metab Syndr 2022;14:44. [PMID: 35317824 DOI: 10.1186/s13098-022-00811-2] [Reference Citation Analysis]
20 Nucera S, Ruga S, Cardamone A, Coppoletta AR, Guarnieri L, Zito MC, Bosco F, Macrì R, Scarano F, Scicchitano M, Maiuolo J, Carresi C, Mollace R, Cariati L, Mazzarella G, Palma E, Gliozzi M, Musolino V, Cascini GL, Mollace V. MAFLD progression contributes to altered thalamus metabolism and brain structure. Sci Rep 2022;12:1207. [PMID: 35075185 DOI: 10.1038/s41598-022-05228-5] [Reference Citation Analysis]
21 Wang J, Liu S, Cao Q, Wu S, Niu J, Zheng R, Bie L, Xin Z, Zhu Y, Wang S, Lin H, Wang T, Xu M, Lu J, Chen Y, Xu Y, Wang W, Ning G, Xu Y, Li M, Bi Y, Zhao Z. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study. Front Med 2022. [PMID: 35507246 DOI: 10.1007/s11684-021-0888-8] [Reference Citation Analysis]
22 Mantovani A, Valenti L. A call to action for fatty liver disease. Liver Int 2021;41:1182-5. [DOI: 10.1111/liv.14907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George J. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35710982 DOI: 10.1038/s41575-022-00635-5] [Reference Citation Analysis]
24 Lee SM, Jung YM, Choi ES, Kwak SH, Koo JN, Oh IH, Kim BJ, Kim SM, Kim SY, Kim GM, Joo SK, Koo BK, Shin S, Norwitz ER, Park CW, Jun JK, Kim W, Park JS. Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01219-2. [PMID: 34798335 DOI: 10.1016/j.cgh.2021.11.007] [Reference Citation Analysis]
25 Zhao J, Zhao Y, Hu Y, Peng J. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cell Mol Biol Lett 2021;26:32. [PMID: 34233623 DOI: 10.1186/s11658-021-00276-7] [Reference Citation Analysis]
26 Di Sessa A, Guarino S, Umano GR, Arenella M, Alfiero S, Quaranta G, Miraglia Del Giudice E, Marzuillo P. MAFLD in Obese Children: A Challenging Definition. Children (Basel) 2021;8:247. [PMID: 33806784 DOI: 10.3390/children8030247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. Journal of Hepatology 2021;74:977-9. [DOI: 10.1016/j.jhep.2020.12.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
28 Wei JY, Xu Z, Li H, Du WQ, Niu BL, Li S, Tian S, Wu J, Chen YL, Li X, Liu ZL, Xiao J, Ren GS, Ran L, Kong LQ. Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China. Int J Med Sci 2021;18:3082-9. [PMID: 34400878 DOI: 10.7150/ijms.60780] [Reference Citation Analysis]
29 George J, Gish RG, Geier A. MAFLD and Cardiovascular Events: What Does the Evidence Show? Clinical Gastroenterology and Hepatology 2021;19:2025-8. [DOI: 10.1016/j.cgh.2021.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]